1. Home
  2. NERV

NERV

Minerva Neurosciences Inc

Logo Minerva Neurosciences Inc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Founded: 2007 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 17.8M IPO Year: 2014
Target Price: $11.00 AVG Volume (30 days): 122.7K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.61 EPS Growth: N/A
52 Week Low/High: $2.04 - $13.49 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: